News

The prescription-only peanut allergy treatment Palforzia® will be discontinued on 31 July 2026, according to its manufacturer, Stallergenes Greer. The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2020.  Palforzia is the only oral immunotherapy approved by the FDA for the treatment…

As part of the natural evolution of our organisation, we see opportunity to further strengthen our capability.  We are inviting expressions of interest from members who would like to join the Board as a Non-Executive Director. This is a unique…

A recent study published in the Journal of Food Protection examined how, when reused, high levels of cashew allergens in frying and roasting oil can transfer to other foods. This sheds light on a potentially overlooked pathway for allergen exposure.…

Under Standard 1.2.3 of the Australia New Zealand Food Standards Code, foods containing bee pollen, propolis or royal jelly must display a mandatory warning or advisory statement due to the risk of severe allergic reactions, including rare fatalities. A recent review…

A newly published study in Scientific Reports sheds light on the complex allergen cross-reactivities that can underlie apparent cockroach allergy, with important implications for how food-related allergic risk is understood. Researchers examined adults with perennial allergic rhinitis who tested positive…

In February 2026, the U.S. Food and Drug Administration (FDA) convened a virtual public meeting and listening session on food allergen thresholds and their potential applications, signalling a major step forward in how allergen risks may be assessed and managed…